Pfizer Q1: What are the latest developments that are expected to receive 16 regulatory approvals within 18 months?

Recently, Pfizer announced its financial results for the first quarter of 2022

The latest research and development progress of the new crown vaccine

Comirnaty, an mRNA vaccine jointly developed by Pfizer and BioNTech, was used as a booster to significantly increase neutralizing antibody levels against the Omicron variant in children aged 5-11

▲The role of Comirnaty enhancement needles in children aged 5-11 (Image source: Pfizer official website)

In addition, in people over 50 years of age, real-world data from Israel showed that receiving a second booster dose during the Omicron epidemic significantly reduced the risk of hospitalization, severe illness, or death due to COVID-19

▲ Comirnaty's second dose booster reduces the risk of hospitalization, severe COVID-19, and death in people over 50 years old (Image source: Pfizer's official website)

Potential 'best-in-class' oral ulcerative colitis drug

Pfizer completed its acquisition of Arena Pharmaceuticals on March 11 this year

Pfizer said that etrasimod's mechanism of action has the potential to treat inflammatory diseases other than ulcerative colitis, and clinical trials to test the efficacy of etrasimod in the treatment of Crohn's disease, alopecia areata, atopic dermatitis, and eosinophilic esophagitis have all entered Phase 2 clinical trials development stage

▲Etrasimod's clinical development project (Image source: Pfizer's official website)

Several clinical trials of JAK3/TEC selective inhibitors are progressing positively

A feature of Pfizer's JAK3/TEC selective inhibitor ritlecitinib is the avoidance of inhibition of JAK1, JAK2, and TYK2 activity

▲Introduction to Ritlecitinib (Image source: Pfizer official website)

In a phase 2b clinical trial for the treatment of vitiligo, patients received significant improvements in the Facial Vitiligo Area Severity Index (F-VASI) after 48 weeks of treatment

▲ The results of the Phase 2b clinical trial of Ritlecitinib in the treatment of vitiligo (Image source: Pfizer official website)

Potential 'best-in-class' anti-RSV therapy

Pfizer recently reached an agreement with ReViral to acquire ReViral for about $525 million to acquire its respiratory syncytial virus (RSV) therapy sisunatovir

▲Introduction to Sisunatovir (Image source: Pfizer official website)

In the treatment of non-small cell lung cancer, the third-generation ALK inhibitor has a positive effect for 3 years

At the recently concluded AACR annual meeting, Pfizer announced the 3-year follow-up results of its third-generation ALK inhibitor lorlatinib (Lorbrena)

▲ Lorlatinib significantly reduces the risk of disease progression or death in patients (Image source: Pfizer official website)

Lorlatinib has also shown good effects in preventing brain metastases due to its ability to cross the blood-brain barrier

▲ Lorlatinib significantly reduces the risk of cancer brain metastases (Image source: Pfizer official website)

Multiple strategies to treat all types of hemophilia

In the treatment of hemophilia, Pfizer's gene therapy for hemophilia B has shown positive results in Phase 1b/2 clinical trials, with an average annual bleeding rate of 0.

In addition, the company's development of marstacimab, a candidate therapy that does not directly target coagulation factors, is a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI)

Image source: Pfizer official website

Pfizer said it expects to receive up to 16 regulatory approvals, up to 19 pivotal clinical trial results, and up to 15 proof-of-concept trial results over the next 18 months

References:

[1] PFIZER REPORTS FIRST-QUARTER 2022 RESULTS.